Esmolol dosage forms and strengths: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi- (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Esmolol}} | {{Esmolol}} | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}}; {{AK}} | ||
==Dosage Forms and Strengths== | ==Dosage Forms and Strengths== | ||
| Line 15: | Line 15: | ||
{{FDA}} | {{FDA}} | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 22:50, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]; Abdurahman Khalil, M.D. [3]
Dosage Forms and Strengths
All BREVIBLOC dosage forms are iso-osmotic solutions of esmolol hydrochloride in sodium chloride[1].
 |
References
Adapted from the FDA Package Insert.